Screening for macroprolactinaemia
Fahie-Wilson and Soule! have produced valuable information regarding the prevalence and nature of macroprolactinaemia in blood samples submitted to the laboratory for analysis of prolactin.
However, 1 believe that the conclusion of their paper, that patients with macroprolactinaemia do not exhibit features of the 'hyperprolactinaemia syndrome', and therefore do not require further investigation and treatment should be treated with caution.
Recent work has shown that macroprolactin is bioactive in vitro, using a rat lymphoma Nb2 assay.? There is presently no good evidence that monomeric prolactin (PRL) is significantly more bioactive in vivo than macro-PRL. Other work! has shown clear evidence of features of the 'hyperprolactinaemic syndrome' in patients with hypermacroprolactinaemia. Scrutiny of Fahie-Wilson and Soule's Table I , showing clinical data relating to subjects with macroprolactinaemia, does not provide convincing evidence of relatively greater activity of monomeric PRL. Some patients with an increased concentration of monomeric PRL appear to have regular ovulatory cycles, while others with a predominant increase in macro-PRL have oligomenorrhea.
What is required now is a prospective study comparing the prevalence of clinical features, presence of pituitary lesions, and response to dopamine agonist therapy in patients with increases in serum concentrations of monomeric PRL and macro-PRL. In the meantime, staff in laboratories running assays which do not detect macro-PRL should not assume that their assay is detecting all cases of clinically relevant hyperprolactinaemia. Laboratories should be aware of the response of their immunoassay to macroprolactin, which can be identified by polyethylene glycol precipitation, centrifugal ultrafiltration, or comparisons of different immunoassay results.
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Biochemistry Department, Law Hospital NHS Trust, Carluke, Lanarkshire ML8 5ER, UK In a recent issue of the Annals, Fame-Wilson and Soule reported on the prevalence of macroprolactin [prolactin (PRL), MW 150-170 kD] as a cause of hyperprolactinaemia in a UK population, using gel filtration chromatography (GFC).l They evaluated the usefulness of precipitation of macroprolactin with polyethylene glycol (PEG) 600 as a simple screening test for the detection of this PRL species in serum. As they rightly alluded to, the use of precipitation with PEG as a screening test has only recently been advocated," and is based on the evidence Letters 
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Irregular periods Normal that macroprolactin is mostly a complex of monomeric prolactin (MW 23 kD) with an immunoglobulin G (IgG) antibody':" which has been named anti-PRL autoantibody.l-' We wish to make further comments on this topical subject as follows.
We have previously published our experience on the use of the PEG precipitation method to screen for anti-PRL autoantibody (APA) in a sample of 51 sera with raised PRL concentrations (>420mU/L) and 35 sera with normal levels of the hormone." In that study, the presence of macroprolactinaemia was established by assessment of the proportion of labelled PRL [ 1251]_ PRL, precipitated by PEG 600 (25% w/w), as described by Hattori et al. 8 Sera which had a percentage of precipitate greater than a cut-off value of 10·6% (determined statistically from combined data on all sera screened) were judged to contain macro-PRL. Free PRL (or PRL recovery) was then assessed in the hyperprolactinaemic sera after precipitation with PEG exactly as described by Fahie-Wilson and Soule.' The PRL assay used was the Chelsea PRL radioimmunoassay kit. Five hyperprolactinaemic sera (9.8%) were judged to contain macroprolactinaemia and all five had PRL recovery less than 40% (Table I) .
The macro-PRL-free sera all had PRL recovery greater than 60%. These findings on PRL recovery are similar to those reported by Fahie-Wilson and Soule. The concordance of results between the two studies, therefore, lends further credence to the PEG precipitation method as a useful screening test for macropro lactinaemia or Ann cu« Biochem 1997: 34 APA-induced hyperprolactinaemia. However, the questions that now need to be addressed in relation to the routine use of this test are: (a) should all requests for serum prolactin with elevated concentrations of the hormone be screened for macroprolactin or should the relevant sera be selected only according to some defined criteria?; (b) will the use of GFC be necessary to confirm cases of macroprolactinaemia identified by the PEG precipitation test? Hopefully, further experience in the application of the screening test should provide answers to these questions.
It should be emphasized that all pathological causes of hyperprolactinaemia must be excluded before the cause of a raised serum PRL in a patient presenting with or without symptoms of the hyperprolactinaemia syndrome is attributed solely to macro-PRL, even when the presence of this PRL species in serum has been established by the appropriate in-vitro techniques. This view is based on the available evidence which indicate that: (i) macroprolactinaemia is sometimes present in association with cause-proven hyperprolactinaemia e.g. prolactinoma.w and (ii) the degree of elevation of serum PRL seen in macroprolactinaemia is sometimes similar to, or even greater than, that considered to be pathognomonic of prolactinomas and other sinister causes of hyperprolactinaemia. 3.8,9 Fahie-Wilson and Soule concluded that none of their macroprolactinaemic patients had clinical evidence of the hyperprolactinaemia syndrome; yet we note that two of the women found by the authors to have macroprolactinaemia (patients 2 and IS) may have presented with unexplained oligomenorrhoea and irregular cycles respectively. Perhaps those two patients should have been classified as symptomatic, since in clinical practice, hyperprolactinaemic women frequently do not exhibit all of the classical features of the hyperprolactinaemia syndrome (i.e. galactorrhoea, amenorrhoea and infertility). Also a significant number of them will present only with mild menstrual disturbances such as irregular cycles or oligomenorrhoea.!" Indeed, only 30%-50% of such individuals will present with galactorrhoea either alone or in combination with the other symptoms. 1O • 11 These are subtle points, but they need clarification in the context of evidence-based practice, especially as the symptomatology and clinical implication of macroprolactinaemia are yet to be fully resolved. Both letters raise the important question of the clinical relevance of this phenomenon. We quite agree that a clinical study is required to accompany our recent paper and this is underway. We have recently reported preliminary conclusions/ which indicate that the great majority of patients with macroprolactinaemia have unequivocally normal reproductive function. Drs Olukoga and Kane have drawn attention to two patients with oligomenorrhoea (patients 2 and IS). Patient 2 has since developed a short menstrual cycle (14--21 days) with menorrhagia, and is principally troubled by obesity. The clinical picture is more that of polycystic ovary syndrome than hyperprolactinaemia. Patient IS has suffered marked weight loss due to anorexia nervosa. The effects of a trial of bromocriptine are not yet known but it seems clinically more likely at present that her menstrual disturbance is related to her weight rather than hyperprolactinaemia. These cases
